1803240-98-3

1803240-98-3 structure

Name: Cefuroxime-d3
Chemical Name: Cefuroxime-d3
CAS Number: 1803240-98-3
Molecular Formula: C₁₆H₁₃D₃N₄O₈S
Molecular Weight: 427.40
Catalog: Signaling Pathways Anti-infection Bacterial
Create Date: 2021-05-10 17:40:39
Modify Date: 2024-01-08 12:11:26
Cefuroxime-d3 is deuterium labeled Cefuroxime (sodium). Cefuroxime sodium is an orally active second-generation cephalosporin antibiotic with increased stability to β-lactamase. Cefuroxime sodium has a broad spectrum activity against Gram-positive and Gram-negative bacteria[1].

Name	Cefuroxime-d3
Synonyms	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 3-[[(aminocarbonyl)oxy]methyl]-7-[[(2Z)-2-(2-furanyl)-2-[(methyl-d3-oxy)imino]-1-oxoethyl]amino]-8-oxo-, (6R,7R)- Cefuroxime-d3 (6R,7R)-3-[(Carbamoyloxy)methyl]-7-{[(2Z)-2-(2-furyl)-2-{[(2H3)methyloxy]imino}acetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

Description	Cefuroxime-d3 is deuterium labeled Cefuroxime (sodium). Cefuroxime sodium is an orally active second-generation cephalosporin antibiotic with increased stability to β-lactamase. Cefuroxime sodium has a broad spectrum activity against Gram-positive and Gram-negative bacteria[1].
Related Catalog	Research Areas >> Infection Signaling Pathways >> Anti-infection >> Bacterial
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
References	[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [2]. Callaghan, et al. Cefuroxime sodium, a New Cephalosporin Antibiotic: Activity in Vitro. Antimicrob Agents Chemother. 1976 Mar;9(3):511-9. [3]. D M Ryan, et al. Cefuroxime sodium, a New Cephalosporin Antibiotic: Activity in Vivo. Antimicrob Agents Chemother. 1976 Mar;9(3):520-5.